

A Clinical Prediction Rule to Identify Febrile Infants 60 Days and Younger at Low Risk for Serious Bacterial Infections

Nathan Kuppermann, MD, MPH; Peter S. Dayan, MD, MSc; Deborah A. Levine, MD; Melissa Vitale, MD; Leah Tzimenatos, MD; Michael G. Tunik, MD; Mary Saunders, MD; Richard M. Ruddy, MD; Genie Roosevelt, MD; Alexander J. Rogers, MD; Elizabeth C. Powell, MD, MPH; Lise E. Nigrovic, MD, MPH; Jared Muenzer, MD; James G. Linakis, MD, PhD; Kathleen Grisanti, MD; David M. Jaffe, MD; John D. Hoyle Jr, MD; Richard Greenberg, MD; Rajender Gattu, MD; Andrea T. Cruz, MD, MPH; Ellen F. Crain, MD, PhD; Daniel M. Cohen, MD; Anne Brayer, MD; Dominic Borgialli, DO, MPH; Bema Bonsu, MD; Lorin Browne, DO; Stephen Blumberg, MD; Jonathan E. Bennett, MD; Shireen M. Atabaki, MD, MPH; Jennifer Anders, MD; Elizabeth R. Alpern, MD, MSCE; Benjamin Miller, MS; T. Charles Casper, PhD; J. Michael Dean, MD, MBA; Octavio Ramilo, MD; Prashant Mahajan, MD, MPH, MBA; for the Febrile Infant Working Group of the Pediatric Emergency Care Applied Research Network (PECARN)

+ Supplemental content

IMPORTANCE In young febrile infants, serious bacterial infections (SBIs), including urinary tract infections, bacteremia, and meningitis, may lead to dangerous complications. However, lumbar punctures and hospitalizations involve risks and costs. Clinical prediction rules using biomarkers beyond the white blood cell count (WBC) may accurately identify febrile infants at low risk for SBIs.

OBJECTIVE To derive and validate a prediction rule to identify febrile infants 60 days and younger at low risk for SBIs.

DESIGN, SETTING, AND PARTICIPANTS Prospective, observational study between March 2011 and May 2013 at 26 emergency departments. Convenience sample of previously healthy febrile infants 60 days and younger who were evaluated for SBIs. Data were analyzed between April 2014 and April 2018.

EXPOSURES Clinical and laboratory data (blood and urine) including patient demographics, fever height and duration, clinical appearance, WBC, absolute neutrophil count (ANC), serum procalcitonin, and urinalysis. We derived and validated a prediction rule based on these variables using binary recursive partitioning analysis.

MAIN OUTCOMES AND MEASURES Serious bacterial infection, defined as urinary tract infection, bacteremia, or bacterial meningitis.

RESULTS We derived the prediction rule on a random sample of 908 infants and validated it on 913 infants (mean age was 36 days, 765 were girls [42%], 781 were white and non-Hispanic [43%], 366 were black [20%], and 535 were Hispanic [29%]). Serious bacterial infections were present in 170 of 1821 infants (9.3%), including 26 (1.4%) with bacteremia, 151 (8.3%) with urinary tract infections, and 10 (0.5%) with bacterial meningitis; 16 (0.9%) had concurrent SBIs. The prediction rule identified infants at low risk of SBI using a negative urinalysis result, an ANC of 4090/ μL or less (to convert to $\times 10^9$ per liter, multiply by 0.001), and serum procalcitonin of 1.71 ng/mL or less. In the validation cohort, the rule sensitivity was 97.7% (95% CI, 91.3-99.6), specificity was 60.0% (95% CI, 56.6-63.3), negative predictive value was 99.6% (95% CI, 98.4-99.9), and negative likelihood ratio was 0.04 (95% CI, 0.01-0.15). One infant with bacteremia and 2 infants with urinary tract infections were misclassified. No patients with bacterial meningitis were missed by the rule. The rule performance was nearly identical when the outcome was restricted to bacteremia and/or bacterial meningitis, missing the same infant with bacteremia.

CONCLUSIONS AND RELEVANCE We derived and validated an accurate prediction rule to identify febrile infants 60 days and younger at low risk for SBIs using the urinalysis, ANC, and procalcitonin levels. Once further validated on an independent cohort, clinical application of the rule has the potential to decrease unnecessary lumbar punctures, antibiotic administration, and hospitalizations.

JAMA Pediatr. doi:10.1001/jamapediatrics.2018.5501
Published online February 18, 2019.

Author Affiliations: Author affiliations are listed at the end of this article.

Group Information: The members of the Febrile Infant Working Group of the Pediatric Emergency Care Applied Research Network (PECARN) appear at the end of this article.

Corresponding Author: Nathan Kuppermann, MD, MPH, Departments of Emergency Medicine and Pediatrics, University of California, Davis School of Medicine, 2315 Stockton Blvd, PSSB Ste 2100, Sacramento, CA 95817 (nkuppermann@ucdavis.edu).

Nearly 500 000 febrile infants are evaluated in US emergency departments (EDs) and other outpatient settings annually.^{1,2} Among febrile infants 60 days and younger, 8% to 13% have serious bacterial infections (SBIs) including urinary tract infections (UTIs), bacteremia, and bacterial meningitis.³⁻⁵ Because missed SBIs, particularly bacteremia and meningitis, may lead to serious complications,^{6,7} the treatment of febrile infants frequently involves lumbar punctures, broad-spectrum antibiotic administration, and hospitalization.

Fever may be the only sign of infection in young infants with SBIs. Clinical observation frequently fails to identify infants with invasive bacterial infections (bacteremia and meningitis),^{8,9} and no single laboratory test result reliably identifies all infants with SBIs.^{6,10-19} Transcriptome analysis holds promise for earlier diagnosis²⁰⁻²³; however, these tests have not been fully evaluated in the clinical setting. The incidence of SBIs in infants has decreased over time,²⁴ making it imperative to balance the consequences of missed SBIs with risks of hospital-related complications, costs, and potential increases in antimicrobial resistance owing to empirical antibiotic treatment.^{6,25}

Clinical prediction rules with decision support can reduce variation in care and limit unnecessary interventions.²⁶⁻²⁹ However, many algorithms for the evaluation of febrile infants combine subjective clinical findings and laboratory markers using pre-existing numerical cutoffs rather than statistically derived values^{11,12,14,15,17,30} and lack precision and specificity, and validation studies have less than ideal accuracy.³¹⁻³³ Biomarkers, such as C-reactive protein and procalcitonin, have been used either alone^{16,18,34-36} or combined with other laboratory and clinical findings^{32,37,38} to risk stratify febrile infants, but further assessment is necessary to identify optimal thresholds and determine their utility for inclusion in prediction rules. We sought to derive and validate an accurate prediction rule in a large, prospectively enrolled, geographically diverse cohort of febrile infants 60 days and younger to identify those at low risk of SBIs.

Methods

Study Design, Setting, and Population

Febrile infants 60 days and younger were recruited in a prospective observational multicenter study evaluating RNA microarray analysis for detection of bacterial infections.^{20,39,40} The parent study has completed 2 grant cycles. The published microarray results include only data obtained during the first grant cycle. The current analytic cohort includes patients enrolled during the first and second grant cycles, between March 2011 and May 2013. Study methods have been previously described³⁹ but are briefly summarized here. The study received institutional review board approval at each site, with permission for data sharing and material transfer. We obtained written informed consent from the legal guardians of enrolled patients.

Infants from whom blood cultures were obtained for evaluation of SBIs during times when research staff were available

Key Points

Question Can clinical features and laboratory tests identify febrile infants 60 days and younger at low risk for serious bacterial infections?

Findings In a cohort of 1821 febrile infants 60 days and younger, 170 (9.3%) had serious bacterial infections, and using recursive partitioning analysis, we derived a low-risk prediction rule involving 3 variables: normal urinalysis, absolute neutrophil count $\leq 4090/\mu\text{L}$, and serum procalcitonin ≤ 1.71 ng/mL. The rule sensitivity was 97.7%, specificity was 60.0%, and negative predictive value was 99.6%; no infant with bacterial meningitis was missed.

Meaning The urinalysis, absolute neutrophil count, and serum procalcitonin levels may accurately identify febrile infants 60 days and younger at low risk for serious bacterial infections.

were eligible (**Figure 1**). Fever was defined by rectal temperature of at least 38°C in the ED, in a prior health care setting, or at home within 24 hours. We excluded infants who appeared critically ill, had received antibiotics in the preceding 48 hours, had histories of prematurity (≤ 36 weeks' gestation), pre-existing medical conditions, indwelling devices, or soft-tissue infections. Patients were not excluded for otitis media. Clinical care was at the discretion of the treating clinician.

Clinical and Laboratory Evaluation


Emergency physicians (faculty or fellows in general or pediatric emergency medicine) performed patient histories and physical examinations, provided assessment of the Yale Observation Scale (YOS) score,⁴¹ and recorded unstructured clinical suspicion of SBI (using 5 risk categories: $<1\%$, $1\%-5\%$, $6\%-10\%$, $11\%-50\%$, or $>50\%$) prior to knowledge of laboratory results. All patients had blood and urine cultures obtained. Cerebrospinal fluid (CSF) testing was performed at the discretion of the treating clinician. To verify that patients discharged from the ED without CSF testing did not have bacterial meningitis, we contacted families of those patients by telephone 8 to 14 days after the ED visit and/or reviewed their medical records. Viral test results were not considered for the prediction rule because these were not typically available for ED decision making, and there was substantial variability among clinicians in their use.⁴²⁻⁴⁵ Band counts were not considered for the prediction rule because they are variably performed across centers¹⁶ and their utility has been questioned.⁴⁶

For procalcitonin measurement, 1 mL of blood was centrifuged and stored at -80°C within 6 hours of the blood draw and shipped to a central laboratory. Procalcitonin results were not available to the treating clinicians.

Definitions and Outcome Measures

Serious bacterial infection was defined by bacterial meningitis, bacteremia, or UTI. We defined UTIs by the growth of a single urine pathogen with (1) at least 1000 cfu/mL for cultures obtained by suprapubic aspiration, (2) at least 50 000 cfu/mL from catheterized specimens, or (3) 10 000 to 50 000 cfu/mL from catheterized specimens in association with an abnormal urinalysis, defined by the presence of

Figure 1. Patient Flow Diagram



^a This includes patients for whom procalcitonin (PCT) could not be sampled, regardless of whether an eligible RNA biosignature sample was obtained in the parent study. SBI indicates serious bacterial infection.

leukocyte esterase, nitrite, or pyuria (>5 white blood cells per high-power field [WBC/hpf]).⁴⁷ This UTI definition was conservatively modified from the American Academy of Pediatrics practice parameter to account for the lower colony counts of bacteria (10 000-50 000 cfu/mL) sometimes present in the urine of young infants with UTIs⁴⁸⁻⁵² in comparison with older infants.⁴⁷ Bacteremia and bacterial meningitis were defined by the growth of a single bacterial pathogen in the blood or CSF, respectively.²⁰ Growth of bacteria not commonly considered pathogens (eg, diphtheroids or coagulase-negative *Staphylococcus*) were categorized a priori as contaminants, and patients with growth of these organisms (meeting no other criteria for SBI) were categorized in the SBI-negative group.

Statistical Analysis

We compared descriptive statistics from patients enrolled in the parent study before procalcitonin levels were collected to the study cohort to detect any important differences. To create the prediction rule, patients who had procalcitonin levels measured were randomly divided into derivation and validation sets. Random sampling was constrained to provide balanced representation of bacteremia, bacterial meningitis, and UTIs between derivation and validation sets. As predictor variables, we included age group (≤ 28 days vs > 28 days), qualifying temperature, duration of fever, YOS score, unstructured clinician suspicion, urinalysis, WBC count, absolute neutrophil count (ANC), and serum procalcitonin level. We performed univariable analyses for each potential predictor using

differences in proportions, with 95% confidence intervals for categorical variables, differences in means with 95% confidence intervals for continuous variables, and medians with interquartile ranges for YOS scores. All *P* values were 2-sided, with *P* values less than .05 considered significant.

Recursive Partitioning Analysis

To identify a low-risk cohort using the derivation set, all potential predictors of SBI were entered into a binary recursive partitioning analysis.⁵³ The algorithm identifies optimal thresholds for each numerical predictor to generate decision trees. We prioritized the sensitivity of the prediction rule by specifying a relative cost of 100 to 1 for failure to identify an SBI vs incorrectly predicting SBI. The final tree was chosen prior to applying the results to the validation set. In both derivation and validation sets, we calculated the prediction rule's sensitivity, specificity, positive and negative predictive values, and likelihood ratios, with corresponding 95% confidence intervals.

Additional Analyses

We performed exploratory analyses to determine whether procalcitonin results could further subdivide the high-ANC group. In addition, because bacteremia and bacterial meningitis are more invasive infections than UTIs, we performed a subanalysis to evaluate the rule accuracy for identifying patients with those infections (including patients with concurrent UTI and bacteremia or meningitis).

We also performed a sensitivity analysis to account for uncertain diagnoses of UTIs in patients with colony counts of 10 000 to 49 999 cfu/hpf and abnormal urinalysis results. Patients in this category were removed from the data set and the recursive partitioning was repeated.

Finally, we performed a multivariable logistic regression analysis to determine whether this would result in a more accurate model. See the eMethods in the Supplement for details.

Salford Predictive Modeler software, version 8.0, was used for all recursive partitioning analyses (Salford Systems). All other statistical analyses and summaries were performed using SAS software, version 9.4 (SAS Institute Inc).

Results

Patient Population

A total of 1896 febrile infants were enrolled (1821 with procalcitonin data analyzable and complete assessments for SBI; Figure 1). One thousand eight hundred six infants (99.2%) had CBCs, 1775 (97.5%) had urinalyses, and 1399 (76.8%) had lumbar punctures performed (including 871 of 1266 infants aged 29-60 days [68.8%]). Of the 1821 infants, 908 were randomly allocated to the derivation set and 913 to the validation set (Table 1); demographic and clinical characteristics were similar between groups. Patients enrolled in the parent study before procalcitonin levels were obtained, and patients from whom procalcitonin levels were not obtained for other reasons were similar to those with procalcitonin measurements (eTable 1 in the Supplement). All patients had blood and urine cultures, and 1383 (76%) had CSF cultures obtained.

Table 1. Patient Characteristics

Characteristic	Sample, No. (%)		
	Derivation (n = 908)	Validation (n = 913)	Overall (N = 1821)
Age, mean (SD), d	35.9 (14.8)	36.1 (15.0)	36.0 (14.9)
Age ≤28 d	280 (30.8)	275 (30.1)	555 (30.5)
Female	387 (42.6)	378 (41.4)	765 (42.0)
Race/ethnicity			
White, non-Hispanic	397 (43.7)	384 (42.1)	781 (42.9)
Black	183 (20.2)	183 (20.0)	366 (20.1)
Asian	20 (2.2)	34 (3.7)	54 (3.0)
Hispanic	263 (29.0)	272 (29.8)	535 (29.4)
Other/missing	45 (5.0)	40 (4.4)	85 (4.7)
Qualifying temperature, mean (SD), °C	38.5 (0.5)	38.5 (0.4)	38.5 (0.4)
Duration of fever prior to ED visit, h			
<12	569 (62.7)	575 (63.0)	1144 (62.8)
12-24	265 (29.2)	254 (27.8)	519 (28.5)
>24	69 (7.6)	75 (8.2)	144 (7.9)
Unknown	5 (0.6)	9 (1.0)	14 (0.8)
YOS, median (IQR)	6.0 (6.0-8.0)	6.0 (6.0-8.0)	6.0 (6.0-8.0)
Clinician suspicion			
<1%	322 (35.5)	361 (39.5)	683 (37.5)
1%-5%	387 (42.6)	366 (40.1)	753 (41.4)
6%-10%	138 (15.2)	127 (13.9)	265 (14.6)
11%-50%	44 (4.8)	42 (4.6)	86 (4.7)
>50%	10 (1.1)	14 (1.5)	24 (1.3)
Unknown	7 (0.8)	3 (0.3)	10 (0.5)
Urinalysis positive	127 (14.0)	149 (16.3)	276 (15.2)
WBC, mean (SD), /μL	10 300 (4500)	10 500 (4.9)	10 400 (4700)
ANC, mean (SD), /μL	4000 (2800)	4200 (3300)	4100 (3100)
PCT, ng/mL, median (IQR)	0.2 (0.2-0.3)	0.2 (0.2-0.3)	0.2 (0.2-0.3)
SBI positive	82 (9.0)	88 (9.6)	170 (9.3)
UTI alone	65 (7.2)	75 (8.3)	140 (7.7)
Bacteremia alone	8 (0.9)	2 (0.2)	10 (0.5)
Meningitis alone	3 (0.3)	1 (0.1)	4 (0.2)
UTI and bacteremia	3 (0.3)	7 (0.8)	10 (0.5)
Bacteremia and meningitis	2 (0.2)	3 (0.3)	5 (0.3)
UTI and bacteremia and meningitis	1 (0.1)	0	1 (0.1)
SBI positive			
Age ≤28 d ^a	36 (12.9)	36 (13.1)	72 (13.0)
UTI alone	28 (10.0)	29 (10.5)	57 (10.3)
Bacteremia alone	3 (1.1)	1 (0.4)	4 (0.7)
Meningitis alone	2 (0.7)	1 (0.4)	3 (0.5)
UTI and bacteremia	1 (0.4)	3 (1.1)	4 (0.7)
Bacteremia and meningitis	1 (0.4)	2 (0.7)	3 (0.5)
UTI and bacteremia and meningitis	1 (0.4)	0	1 (0.2)
Age >28 d ^a	46 (7.3)	52 (8.2)	98 (7.7)
UTI alone	37 (5.9)	46 (7.2)	83 (6.6)
Bacteremia alone	5 (0.8)	1 (0.2)	6 (0.5)
Meningitis alone	1 (0.2)	0	1 (0.1)
UTI and bacteremia	2 (0.3)	4 (0.6)	6 (0.5)
Bacteremia and meningitis	1 (0.2)	1 (0.2)	2 (0.2)
UTI and bacteremia and meningitis	0	0	0

Abbreviations: ANC, absolute neutrophil count; ED, emergency department; IQR, interquartile range; PCT, procalcitonin; SBI, serious bacterial infection; UTI, urinary tract infection; WBC, white blood cell count; YOS, Yale Observation Scale score.

SI conversion factors: To convert ANC to $\times 10^9$ per liter, multiply by 0.001; WBC to $\times 10^9$ per liter, multiply by 0.001.

^a Percentages are calculated out of all patients in the referenced age category (n = 280 and 275 for 28 days and younger, n = 628 and 638 for older than 28 days).

No patients who did not have CSF cultures obtained were later found to have bacterial meningitis. Follow-up information for these patients was based on observation in the hospital

(n = 178), telephone follow-up (n = 216), or medical record review (n = 44). Serious bacterial infections were diagnosed in 170 infants (9.3%; 95% CI, 8.1-10.8), including 151 (8.3%;

Table 2. Univariable Analysis of Combined Derivation and Validation Cohorts

Characteristic	SBI Status, No. (%)		Difference (95% CI)
	Positive (n = 170)	Negative (n = 1651)	
Age, mean (SD), d	33.0 (15.1)	36.4 (14.8)	-3.3 (-5.7 to -0.9)
Age ≤ 28 d	72 (42.4)	483 (29.3)	13.1% (5.4 to 20.8)
Qualifying temperature, mean (SD), °C	38.7 (0.5)	38.5 (0.4)	0.2 (0.1 to 0.3)
Duration of fever prior to ED visit, h			
<12	106 (63.5)	1038 (63.3)	0.2% (-7.5 to 7.8)
12-24	49 (29.3)	470 (28.7)	0.7% (-6.6 to 7.9)
>24	12 (7.2)	132 (8.0)	-0.9% (-5.0 to 3.3)
YOS, median (IQR) ^a	6.0 (6.0 to 10.0)	6.0 (6.0 to 8.0)	
Clinician suspicion			
<1%	36 (21.4)	647 (39.4)	-18.0% (-24.6 to -11.3)
1%-5%	75 (44.6)	678 (41.3)	3.4% (-4.5 to 11.3)
6%-10%	27 (16.1)	238 (14.5)	1.6% (-4.2 to 7.4)
11%-50%	20 (11.9)	66 (4.0)	7.9% (2.9 to 12.9)
>50%	10 (6.0)	14 (0.9)	5.1% (1.5 to 8.7)
Urinalysis positive	141 (82.9)	135 (8.2)	74.8% (69.0 to 80.6)
WBC, mean (SD), /μL	14 300 (6100)	10 000 (4300)	4300 (3400 to 5300)
ANC, mean (SD), /μL	7700 (4500)	3700 (2600)	4000 (3300 to 4700)
PCT, ng/mL, median (IQR)	0.7 (0.3 to 3.4)	0.2 (0.2 to 0.3)	0.5 (0.4 to 0.6)

Abbreviations: ANC, absolute neutrophil count; ED, emergency department; IQR, interquartile range; PCT, procalcitonin; SBI, serious bacterial infection; WBC, white blood cell count; YOS, Yale Observation Scale score.

SI conversion factors: To convert ANC to $\times 10^9$ per liter, multiply by 0.001; WBC to $\times 10^9$ per liter, multiply by 0.001.

^a The P value for the associated Wilcoxon rank sum test is 0.0294.

95% CI, 7.1-9.6) with UTIs, 26 (1.4%; 95% CI, 1.0-2.1) with bacteremia, and 10 (0.5%; 95% CI, 0.3-1.0) with bacterial meningitis; 16 (0.9%; 95% CI, 0.5-1.4) had concurrent bacterial infections (eTable 2 in the Supplement). Of the 16 with multiple infections, 1 had UTI, bacteremia, and meningitis; 5 had bacteremia and meningitis; and 10 had UTI and bacteremia. Four patients had herpes simplex virus infections (all were hospitalized). Three were younger than 28 days (aged 10, 12, and 20 days) and had herpes simplex virus in the CSF; the other was aged 33 days and had herpes simplex virus detected in a nasopharyngeal swab only.

Univariable Analysis

The associations between potential predictors and SBI are shown in Table 2. Although the groups with and without SBIs were similar in mean age, infants with SBIs were more likely to be 28 days or younger, have higher temperatures, WBC counts and ANC, and procalcitonin levels. Increased clinician suspicion was also associated with increased SBI risk.

Recursive Partitioning Analysis

The decision tree retained 3 variables, urinalysis, ANC, and procalcitonin, that together identified a group of infants at low risk of SBI (Figure 2). In the derivation set of 908 infants with a rate of SBI of 9.0%, a negative urinalysis, ANC of 4090/ μ L or lower (to convert to $\times 10^9$ per liter, multiply by 0.001), and a serum procalcitonin level of 1.71 ng/mL or lower identified a low-risk group of 522 infants, with an SBI risk of 0.2% (1 infant). The sensitivity of the decision rule in the derivation set was 98.8% (95% CI, 92.5%-99.9%). In the validation set, the rule identified a low-risk group of 497 infants with an SBI risk of 0.4% (2 infants), yielding a sensitivity of 97.7% (95% CI, 91.3%-99.6%). Other model test characteristics are reported in Figure 2. The types of SBIs in

each risk category (ie, each cell of the decision tree) are shown in eFigures 1 and 2 in the Supplement. One patient in the derivation set (with *Enterobacter cloacae* bacteremia) and 2 patients in the validation set (with UTIs with negative urinalyses) with SBIs were misclassified by the prediction rule (Table 3). In eFigure 3 in the Supplement, we rounded the ANC to 4000/ μ L and serum procalcitonin to 1.7 ng/mL; in eFigure 4 in the Supplement, we rounded the ANC to 4000/ μ L and serum procalcitonin to a commonly accepted cutoff value of 0.5 ng/mL. With these easier-to-apply cutoffs, the model sensitivities and negative predictive values were nearly identical to the empirically derived rule, but specificities were slightly lower.


Of 1266 infants aged 29 to 60 days, 776 (61.3%) were at low risk for the prediction rule, and 523 of these 776 (67.4%) had lumbar punctures performed. This number represents potential lumbar punctures spared in this age group for low-risk patients.

Additional Analyses

To determine whether we could further identify a low-risk cohort among patients with negative urinalyses but with ANC counts greater than the threshold (4090/ μ L), we explored that branch of the tree in the full cohort using recursive partitioning (eFigure 5 in the Supplement). Among the 500 infants in that risk category, there were 153 (30.6%) with procalcitonin levels of 0.18 ng/mL or lower. Only 1 of 153 (0.7%; 95% CI, 0.1%-3.6%) had an SBI (*S aureus* bacteremia).

When patients with UTIs alone were removed from the cohort, the prediction rule performed with similar accuracy for identifying patients with bacteremia and bacterial meningitis (eFigure 6 in the Supplement). In that analysis, the sensitivity of the rule was 96.7% (95% CI, 83.3-99.4) and specificity was 61.5% (95% CI, 59.2-63.9).

Figure 2. Recursive Partitioning Analysis



	Derivation, No.			Validation, No.		
	SBI	No SBI	Total	SBI	No SBI	Total
SBI per rule	81	305	386	86	330	416
No SBI per rule	1	521	522	2	495	497
Total	82	826	908	88	825	913

	Derivation, No.	Validation, No.
Prediction rule sensitivity (95% CI), %	98.8 (92.5-99.9)	97.7 (91.3-99.6)
Prediction rule specificity (95% CI), %	63.1 (59.7-66.4)	60.0 (56.6-63.3)
Negative predictive value (95% CI), %	99.8 (98.8-100.0)	99.6 (98.4-99.9)
Positive predictive value (95% CI), %	21.0 (17.1-25.5)	20.7 (16.9-25.0)
Negative likelihood ratio (95% CI)	0.02 (0.003-0.14)	0.04 (0.01-0.15)
Positive likelihood ratio (95% CI)	2.68 (2.44 - 2.93)	2.44 (2.23-2.67)

Only the derivation cohort is shown in the tree portion of the figure. Overall classification counts and characteristics are shown for both the derivation and validation cohorts below the classification tree. SI conversion factor: To convert absolute neutrophil count (ANC) to $\times 10^9$ per liter, multiply by 0.001. PCT indicates procalcitonin; SBI, serious bacterial infection.

Table 3. Misclassified Patients With SBIs^a

Age, d	Qualifying Temperature, °C	YOS	Clinician Suspicion, %	Disposition of Infant After ED Visit	Urinalysis	WBC, /μL	ANC, /μL	Bands, %	PCT, ng/mL	CSF	SBI
30	38.1	6	6-10	Admitted	Negative	6700	2700	0 (B:N 0)	0.14	Negative	<i>Enterobacter cloacae</i> bacteremia
55	38.4	8	1-5	Discharged	Negative	3800	2200	3 (B:N 0.05)	0.20	Negative	<i>Escherichia coli</i> UTI
36	38.5	6	1-5	Admitted	Negative	2300	900	12 (B:N 0.3)	0.16	Negative	<i>Pseudomonas aeruginosa</i> UTI

Abbreviations: ANC, absolute neutrophil count; B:N, band-to-neutrophil ratio; CSF, cerebrospinal fluid; ED, emergency department; PCT, procalcitonin; SBI, serious bacterial infection; UTI, urinary tract infection; WBC, white blood cell count; YOS, Yale Observation Scale score.

^a The first patient had *Enterobacter cloacae* bacteremia and was in the derivation data set. This patient was admitted to an observation unit for poor feeding without antibiotic treatment. After notification of the positive blood culture at 17 hours, a repeated blood culture was obtained, and the patient

started receiving parenteral antibiotics. The repeated blood culture (prior to antibiotics) was negative and the patient was treated for 7 days with antibiotics, had an uneventful clinical course, and had a final diagnosis of transient bacteremia. The other 2 patients with SBIs who were misclassified were in the validation data set and had positive urine cultures with normal urinalyses (one with *Escherichia coli* growing 55 000 cfu/mL and the other with *Pseudomonas aeruginosa* growing >100 000 cfu/mL). Both were treated with uneventful courses.

In a sensitivity analysis, we reclassified 17 patients with urine culture colony counts of less than 50 000 cfu/mL as SBI-negative. When applied to the new analytic cohort, the recursive partitioning analysis selected the same variables and numerical cutoffs, and the model had similar test accuracies (data not shown).

When we compared multivariable logistic regression analysis with the recursive partitioning analysis, we found inferior test characteristics in the former. For details, see the eResults in the Supplement.

Discussion

In this large, prospective, multicenter study, we derived and validated a highly accurate prediction rule to identify febrile infants 60 days and younger at low risk of SBIs using 3 laboratory test results: the urinalysis, ANC, and serum procalcitonin levels. Neither clinician suspicion nor the YOS added significantly to the rule, as we and others have previously demonstrated.^{8,9} The prediction rule had high sensitivity for

identifying infants with SBIs and high negative predictive value while maintaining moderately high specificity. The lower end of the 95% confidence interval of the negative predictive value in the validation set was 98.4%, leaving a small potential false-negative rate. Importantly, the rule does not require CSF data, potentially obviating the need for routine lumbar punctures for many young febrile infants provided that further external validation confirms accuracy. Furthermore, the rule is straightforward and uses objective variables, simplifying implementation. Rounding the numerical thresholds of the ANC and serum procalcitonin to easier-to-apply numbers resulted in nearly identical model test characteristics.

The better test characteristics of the current prediction rule compared with many previously proposed likely reflects the prospective study design, use of large derivation and validation cohorts, objective laboratory variables at statistically identified thresholds, inclusion of serum procalcitonin, and multivariable statistical modeling to derive and validate the rule. Among commonly used rules not involving newer biomarkers (mainly developed during an era of higher prevalence of SBIs in febrile infants), several, including the Philadelphia, Rochester, Boston, and Pittsburgh criteria,^{11,15,17,54} were not statistically derived and therefore lacked optimal balance between test sensitivity (avoiding missed SBIs) and specificity (preventing overtesting and overtreatment of patients without SBIs). These models included WBC counts at standard thresholds (5000/mL, 15 000/mL, and 20 000/mL [to convert to $\times 10^9$ per liter, multiply by 0.001]), rather than thresholds determined statistically, limiting diagnostic accuracy.^{13,16,55} Furthermore, several previous rules include data from lumbar punctures, an invasive procedure that is not required in our rule. Nonetheless, the sensitivity of our rule is as least as high, and the specificity is higher than several previous rules.^{11,15,56,57} Our data contribute important information to the decades-long debate about the necessity of lumbar punctures and hospitalizations in young febrile infants.^{3,58,59} Our data also contribute important information to guide initiatives aimed at decreasing variability in the approach to young febrile infants and minimizing unnecessary testing and hospitalizations.⁶⁰

Prediction rules for young febrile infants developed in the past decade include newer blood tests that are more sensitive and/or specific for SBI than the WBC count.^{16,18,38,61-63} The “Step-by-Step” rule combined both clinical factors (patient appearance) and laboratory factors (leukocyturia and procalcitonin, C-reactive protein, and ANC levels) in febrile infants aged 22 to 90 days.^{32,38,64} That model had a sensitivity of 98.9% to detect all SBIs and a sensitivity of 92.0% to detect invasive bacterial infections (bacteremia or bacterial meningitis).³⁸ In contrast, our model was derived on a different age group (0-60 days) and does not exclude infants with symptoms or signs of respiratory infections. Our multivariable approach identified ANC and procalcitonin thresholds that maximize test accuracy.

Procalcitonin is particularly sensitive for detecting bacteremia and bacterial meningitis in young febrile infants^{16,18} and is widely available for clinical use, requiring only

200 μ L of serum and having a turnaround time of 30 to 120 minutes.⁶⁵ Not only is the test accuracy of procalcitonin substantially better than the WBC and ANC, but it also surpasses that of C-reactive protein.^{19,66} The better test characteristics of procalcitonin vs C-reactive protein is perhaps owing to the earlier rise in procalcitonin in response to systemic infection.⁶⁶ Our data add to this information by demonstrating ideal thresholds for procalcitonin interpretation in conjunction with other laboratory measurements used in practice.

Similar to previous evaluations of prediction rules, our rule misclassified a few patients with SBIs. One patient classified as low risk had *Enterobacter cloacae* bacteremia. However, a repeated blood culture prior to antibiotic administration was negative, and the patient was treated with antibiotics with an uneventful course. The 2 patients with UTIs who were misclassified had negative urinalysis results possibly indicating asymptomatic bacteriuria.⁶⁷

Limitations

Our study has limitations. We enrolled patients based on research coordinator availability; however, rates of specific SBIs were similar to prior studies in similar populations,³⁻⁵ suggesting that the enrolled sample was representative. In addition, we did not study biomarkers other than procalcitonin. However, previous literature strongly suggests that procalcitonin has superior test characteristics for bacteremia and bacterial meningitis than C-reactive protein and other biomarkers.^{16,18,19} Additionally, we did not evaluate viral testing in the prediction rule because these tests were not part of the protocol nor uniformly performed at the study sites. However, prior literature has shown that identification of viral pathogens diminishes but does not eliminate the risk of SBI in young febrile infants,^{5,16,43,68,69} and those results are often unavailable for ED decision making. Furthermore, although our sample included 170 patients with SBIs, only 30 had bacteremia or bacterial meningitis, reflecting the current epidemiology of SBIs in this age group. Therefore, validation of our findings on cohorts with greater numbers of invasive infections is desirable before implementation. Finally, until further validation of the prediction rule, clinicians must remain most cautious with infants younger than 28 days, in whom the risks of bacteremia and bacterial meningitis as well as herpes encephalitis⁷⁰ are the greatest. In our sample, similar to previous reports,⁷⁰ 0.2% had herpes simplex infections. All 3 infants with herpes encephalitis were in the first month of life, further highlighting the need for caution in this age group.

Conclusions

We derived and validated an accurate prediction rule to identify febrile infants 60 days and younger at low risk for SBIs using 3 easily obtainable, objective variables: the urinalysis, the ANC, and serum procalcitonin. Once further validated, implementation of the rule has the potential to substantially decrease the use of lumbar punctures, broad-spectrum antibiotics, and hospitalization for many febrile infants 60 days and younger.

ARTICLE INFORMATION

Accepted for Publication: December 4, 2018.

Published Online: February 18, 2019.
doi:10.1001/jamapediatrics.2018.5501

Author Affiliations: Departments of Emergency Medicine and Pediatrics, University of California, Davis School of Medicine, Sacramento (Kuppermann); Division of Emergency Medicine, Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, New York (Dayan); Department of Pediatrics, Bellevue Hospital, New York University Langone Medical Center, New York, New York (Levine, Tunik); Division of Emergency Medicine, Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (Vitale); Department of Emergency Medicine, University of California, Davis School of Medicine, Sacramento (Tzimenatos); Department of Pediatrics, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee (Saunders); Children's Hospital of Colorado, University of Colorado School of Medicine, Aurora (Saunders); Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio (Ruddy); Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio (Ruddy); Department of Pediatrics, The Colorado Children's Hospital, University of Colorado, Denver (Roosevelt); Departments of Emergency Medicine and Pediatrics, University of Michigan School of Medicine, Ann Arbor (Rogers); Division of Emergency Medicine, Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Powell); Division of Emergency Medicine, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts (Nigrovic); Division of Emergency Medicine, Department of Pediatrics, St Louis Children's Hospital, Washington University, St Louis, Missouri (Muenzer, Jaffe); Division of Emergency Medicine, Phoenix Children's Hospital, Phoenix, Arizona (Muenzer); Department of Emergency Medicine and Pediatrics, Hasbro Children's Hospital, Providence, Rhode Island (Linakis); Brown University School of Medicine, Providence, Rhode Island (Linakis); Department of Pediatrics, Women and Children's Hospital of Buffalo, State University of New York at Buffalo School of Medicine (Grisanti); Department of Emergency Medicine, Helen DeVos Children's Hospital of Spectrum Health, Grand Rapids, Michigan (Hoyle); Departments of Emergency Medicine and Pediatrics, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo (Hoyle); Division of Emergency Medicine, Department of Pediatrics, Primary Children's Medical Center, University of Utah, Salt Lake City (Greenberg); Division of Emergency Medicine, Department of Pediatrics, University of Maryland Medical Center, Baltimore (Gattu); Sections of Emergency Medicine and Infectious Diseases, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston (Cruz); Department of Pediatrics, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York (Crain, Blumberg); Division of Emergency Medicine, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio

(Cohen, Bonsu); The Ohio State University School of Medicine, Columbus (Cohen, Bonsu, Ramilo); Departments of Emergency Medicine and Pediatrics, University of Rochester Medical Center, Rochester, New York (Brayer); Department of Emergency Medicine, Hurley Medical Center, Flint, Michigan (Borgialli); University of Michigan School of Medicine, Ann Arbor (Borgialli); Departments of Pediatrics and Emergency Medicine, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee (Browne); Division of Emergency Medicine, Alfred I. duPont Hospital for Children, Nemours Children's Health System, Thomas Jefferson School of Medicine, Wilmington, Delaware (Bennett); Division of Emergency Medicine, Department of Pediatrics, Children's National Medical Center, The George Washington School of Medicine and Health Sciences, Washington, DC (Atabaki); Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland (Anders); Division of Emergency Medicine, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (Alpern); Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Alpern); Department of Pediatrics, University of Utah School of Medicine, Salt Lake City (Miller, Casper, Dean); Division of Pediatric Infectious Diseases and Center for Vaccines and Immunity, Nationwide Children's Hospital, Columbus, Ohio (Ramilo); Division of Emergency Medicine, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University, Detroit, Michigan (Mahajan); Department of Emergency Medicine, University of Michigan School of Medicine, Ann Arbor (Mahajan).

Author Contributions: Dr Casper and Mr Miller had full access to study data and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Kuppermann, Dayan, Dean, Ramilo, Mahajan.

Acquisition, analysis, or interpretation of data: Kuppermann, Dayan, Levine, Vitale, Tzimenatos, Tunik, Saunders, Ruddy, Roosevelt, Rogers, Powell, Nigrovic, Muenzer, Linakis, Grisanti, Jaffe, Hoyle, Greenberg, Gattu, Cruz, Crain, Cohen, Brayer, Borgialli, Bonsu, Browne, Blumberg, Bennett, Atabaki, Anders, Alpern, Miller, Casper, Dean, Ramilo, Mahajan.

Drafting of the manuscript: Kuppermann, Dayan, Mahajan.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Kuppermann, Dayan, Miller, Casper, Mahajan.

Obtained funding: Kuppermann, Dean, Ramilo, Mahajan.

Administrative, technical, or material support: Kuppermann, Miller, Casper, Dean, Ramilo, Mahajan.

Supervision: Kuppermann, Dayan, Levine, Vitale, Tzimenatos, Tunik, Saunders, Ruddy, Roosevelt, Rogers, Powell, Nigrovic, Linakis, Grisanti, Jaffe, Hoyle, Greenberg, Cruz, Crain, Cohen, Brayer, Borgialli, Browne, Blumberg, Bennett, Atabaki, Alpern, Miller, Casper, Dean, Ramilo, Mahajan.

Conflict of Interest Disclosures: Dr Ramilo reports personal fees from Abbvie, Janssen, Sanofi, Merck,

Pfizer, and Regeneron and grants from Janssen. All these fees and grants are not related to this study. Dr Hoyle holds the US patents of 2 drug dosing devices. Currently, there are no licensing arrangements, royalty streams or other financial arrangements. No other disclosures were reported.

Funding/Support: This study was supported in part by grant H34MCO8509 from Health Resources and Services Administration, Emergency Services for Children and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (grant R01HD062477). This project was also supported in part by the Health Resources and Services Administration, Maternal and Child Health Bureau, Emergency Medical Services for Children Network Development Demonstration Program under cooperative agreements U03MCO0008, U03MCO0001, U03MCO0003, U03MCO0006, U03MCO0007, U03MC22684, and U03MC22685.

Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: The authors listed in the byline reflect the full membership of the Febrile Infant Working Group of the Pediatric Emergency Care Applied Research Network (PECARN).

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by Health Resources and Services Administration, Department of Health and Human Services, or the US government.

Meeting Presentation: The material was presented in part at the Society for Academic Emergency Medicine National Meeting; May 13, 2015; San Diego, California.

Additional Contributions: The authors thank the research coordinators in PECARN and the project staff at the Data Coordinating Center at the University of Utah; Emily Kim, MPH, Department of Emergency Medicine, University of California, Davis School of Medicine; and Elizabeth B. Duffy, MA, Department of Emergency Medicine, University of Michigan, for their diligent and meticulous work. No compensation was received from a funding sponsor for these contributions.

REFERENCES

1. McCaig LF, Nawar EW. National Hospital Ambulatory Medical Care Survey: 2004 emergency department summary. *Adv Data*. 2006;372(372):1-29.
2. Woll C, Neuman MI, Aronson PL. Management of the febrile young infant: update for the 21st century. *Pediatr Emerg Care*. 2017;33(11):748-753. doi:10.1097/PEC.0000000000001303
3. Aronson PL, Thurm C, Alpern ER, et al; Febrile Young Infant Research Collaborative. Variation in care of the febrile young infant <90 days in US

- pediatric emergency departments. *Pediatrics*. 2014;134(4):667-677. doi:10.1542/peds.2014-1382
4. Biondi E, Evans R, Mischler M, et al. Epidemiology of bacteremia in febrile infants in the United States. *Pediatrics*. 2013;132(6):990-996. doi:10.1542/peds.2013-1759
 5. Blaschke AJ, Korgenski EK, Wilkes J, et al. Rhinovirus in febrile infants and risk of bacterial infection. *Pediatrics*. 2018;141(2):e20172384. doi:10.1542/peds.2017-2384
 6. Byington CL, Reynolds CC, Korgenski K, et al. Costs and infant outcomes after implementation of a care process model for febrile infants. *Pediatrics*. 2012;130(1):e16-e24. doi:10.1542/peds.2012-0127
 7. Klinger G, Chin CN, Beyene J, Perlman M. Predicting the outcome of neonatal bacterial meningitis. *Pediatrics*. 2000;106(3):477-482. doi:10.1542/peds.106.3.477
 8. Baker MD, Avner JR, Bell LM. Failure of infant observation scales in detecting serious illness in febrile, 4- to 8-week-old infants. *Pediatrics*. 1990;85(6):1040-1043.
 9. Nigrovic LE, Mahajan PV, Blumberg SM, et al; Febrile Infant Working Group of the Pediatric Emergency Care Applied Research Network (PECARN). The Yale Observation Scale score and the risk of serious bacterial infections in febrile infants. *Pediatrics*. 2017;140(1):e20170695. doi:10.1542/peds.2017-0695
 10. Aronson PL, Wang ME, Shapiro ED, et al; Febrile Young Infant Research Collaborative. Risk stratification of febrile infants \leq 60 days old without routine lumbar puncture. *Pediatrics*. 2018;142(6):e20181879. doi:10.1542/peds.2018-1879
 11. Baker MD, Bell LM, Avner JR. Outpatient management without antibiotics of fever in selected infants. *N Engl J Med*. 1993;329(20):1437-1441. doi:10.1056/NEJM19931113292001
 12. Baskin MN, Fleisher GR, O'Rourke EJ. Identifying febrile infants at risk for a serious bacterial infection. *J Pediatr*. 1993;123(3):489-490. doi:10.1016/S0022-3476(05)81769-X
 13. Cruz AT, Mahajan P, Bonsu BK, et al; Febrile Infant Working Group of the Pediatric Emergency Care Applied Research Network. Accuracy of complete blood cell counts to identify febrile infants 60 days or younger with invasive bacterial infections. *JAMA Pediatr*. 2017;171(11):e172927. doi:10.1001/jamapediatrics.2017.2927
 14. Dagan R, Sofer S, Phillip M, Shachak E. Ambulatory care of febrile infants younger than 2 months of age classified as being at low risk for having serious bacterial infections. *J Pediatr*. 1988;112(3):355-360. doi:10.1016/S0022-3476(88)80312-3
 15. Herr SM, Wald ER, Pitetti RD, Choi SS. Enhanced urinalysis improves identification of febrile infants ages 60 days and younger at low risk for serious bacterial illness. *Pediatrics*. 2001;108(4):866-871. doi:10.1542/peds.108.4.866
 16. Hui C, Neto G, Tsertsvadze A, et al. Diagnosis and management of febrile infants (0-3 months). *Evid Rep Technol Assess (Full Rep)*. 2012;205(205):1-297.
 17. Jaskiewicz JA, McCarthy CA, Richardson AC, et al; Febrile Infant Collaborative Study Group. Febrile infants at low risk for serious bacterial infection: an appraisal of the Rochester criteria and implications for management. *Pediatrics*. 1994;94(3):390-396.
 18. Milcent K, Faesch S, Gras-Le Guen C, et al. Use of procalcitonin assays to predict serious bacterial infection in young febrile infants. *JAMA Pediatr*. 2016;170(1):62-69. doi:10.1001/jamapediatrics.2015.3210
 19. Yo CH, Hsieh PS, Lee SH, et al. Comparison of the test characteristics of procalcitonin to C-reactive protein and leukocytosis for the detection of serious bacterial infections in children presenting with fever without source: a systematic review and meta-analysis. *Ann Emerg Med*. 2012;60(5):591-600. doi:10.1016/j.annemergmed.2012.05.027
 20. Mahajan P, Kuppermann N, Mejias A, et al; Pediatric Emergency Care Applied Research Network (PECARN). Association of RNA biosignatures with bacterial infections in febrile infants aged 60 days or younger. *JAMA*. 2016;316(8):846-857. doi:10.1001/jama.2016.9207
 21. Herberg JA, Kaforou M, Wright VJ, et al; IRIS Consortium. Diagnostic test accuracy of a 2-transcript host RNA signature for discriminating bacterial vs viral infection in febrile children. *JAMA*. 2016;316(8):835-845. doi:10.1001/jama.2016.11236
 22. Ramilo O, Allman W, Chung W, et al. Gene expression patterns in blood leukocytes discriminate patients with acute infections. *Blood*. 2007;109(5):2066-2077. doi:10.1182/blood-2006-02-002477
 23. Hu X, Yu J, Crosby SD, Storch GA. Gene expression profiles in febrile children with defined viral and bacterial infection. *Proc Natl Acad Sci U S A*. 2013;110(31):12792-12797. doi:10.1073/pnas.1302968110
 24. Biondi EA, Byington CL. Evaluation and management of febrile, well-appearing young infants. *Infect Dis Clin North Am*. 2015;29(3):575-585. doi:10.1016/j.idc.2015.05.008
 25. DeAngelis C, Joffe A, Wilson M, Willis E. Iatrogenic risks and financial costs of hospitalizing febrile infants. *Am J Dis Child*. 1983;137(12):1146-1149.
 26. Dayan PS, Ballard DW, Tham E, et al; Pediatric Emergency Care Applied Research Network (PECARN); Clinical Research on Emergency Services and Treatment (CREST) Network; and Partners Healthcare; Traumatic Brain Injury-Knowledge Translation Study Group. Use of traumatic brain injury prediction rules with clinical decision support. *Pediatrics*. 2017;139(4):e20162709. doi:10.1542/peds.2016-2709
 27. Kuppermann N, Holmes JF, Dayan PS, et al; Pediatric Emergency Care Applied Research Network (PECARN). Identification of children at very low risk of clinically-important brain injuries after head trauma: a prospective cohort study. *Lancet*. 2009;374(9696):1160-1170. doi:10.1016/S0140-6736(09)61558-0
 28. Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. *JAMA*. 1997;277(6):488-494. doi:10.1001/jama.1997.03540300056034
 29. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and methodological standards. *N Engl J Med*. 1985;313(13):793-799. doi:10.1056/NEJM198509263131306
 30. Baker MD, Avner JR. The febrile infant: what's new? *Clin Pediatr Emerg Med*. 2008;9(4):213-220. doi:10.1016/j.cpepm.2008.09.005
 31. Kadish HA, Loveridge B, Tobey J, Bolte RG, Corneli HM. Applying outpatient protocols in febrile infants 1-28 days of age: can the threshold be lowered? *Clin Pediatr (Phila)*. 2000;39(2):81-88. doi:10.1177/000992280003900202
 32. Mintegi S, Gomez B, Martinez-Virumbrales L, Morientes O, Benito J. Outpatient management of selected young febrile infants without antibiotics. *Arch Dis Child*. 2017;102(3):244-249. doi:10.1136/archdischild-2016-310600
 33. Garra G, Cunningham SJ, Crain EF. Reappraisal of criteria used to predict serious bacterial illness in febrile infants less than 8 weeks of age. *Acad Emerg Med*. 2005;12(10):921-925. doi:10.1197/j.aem.2005.06.006
 34. Hernández-Bou S, Trenchs V, Vanegas MI, Valls AF, Luaces C. Evaluation of the bedside Quikread go[®] CRP test in the management of febrile infants at the emergency department. *Eur J Clin Microbiol Infect Dis*. 2017;36(7):1205-1211. doi:10.1007/s10096-017-2910-2
 35. Li W, Luo S, Zhu Y, Wen Y, Shu M, Wan C. C-reactive protein concentrations can help to determine which febrile infants under three months should receive blood cultures during influenza seasons. *Acta Paediatr*. 2017;106(12):2017-2024. doi:10.1111/apa.14022
 36. Maniavi V, Dauber A, Weiss S, Nylen E, Becker KL, Bachur R. Procalcitonin in young febrile infants for the detection of serious bacterial infections. *Pediatrics*. 2008;122(4):701-710. doi:10.1542/peds.2007-3503
 37. England JT, Del Vecchio MT, Aronoff SC. Use of serum procalcitonin in evaluation of febrile infants: a meta-analysis of 2317 patients. *J Emerg Med*. 2014;47(6):682-688. doi:10.1016/j.jemermed.2014.07.034
 38. Gomez B, Mintegi S, Bressan S, Da Dalt L, Gervaix A, Lacroix L; European Group for Validation of the Step-by-Step Approach. Validation of the "Step-by-Step" approach in the management of young febrile infants. *Pediatrics*. 2016;138(2):e20154381. doi:10.1542/peds.2015-4381
 39. Mahajan P, Kuppermann N, Suarez N, et al; Febrile Infant Working Group for the Pediatric Emergency Care Applied Research Network (PECARN). RNA transcriptional biosignature analysis for identifying febrile infants with serious bacterial infections in the emergency department: a feasibility study. *Pediatr Emerg Care*. 2015;31(1):1-5. doi:10.1097/PEC.0000000000000324
 40. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann Intern Med*. 2015;162(1):W1-73. doi:10.7326/M14-0698
 41. McCarthy PL, Sharpe MR, Spiesel SZ, et al. Observation scales to identify serious illness in febrile children. *Pediatrics*. 1982;70(5):802-809.
 42. Aronson PL, Lyons TW, Cruz AT, et al; Pediatric Emergency Medicine Clinical Research Network (PEM CRC) Herpes Simplex Virus (HSV) Study Group. Impact of enteroviral polymerase chain reaction testing on length of stay for infants 60 days old or younger. *J Pediatr*. 2017;189:169-174.e2. doi:10.1016/j.jpeds.2017.06.021

43. Byington CL, Enriquez FR, Hoff C, et al. Serious bacterial infections in febrile infants 1 to 90 days old with and without viral infections. *Pediatrics*. 2004;113(6):1662-1666. doi:10.1542/peds.113.6.1662
44. DePorre A, Williams DD, Schuster J, et al. Evaluating the impact of implementing a clinical practice guideline for febrile infants with positive respiratory syncytial virus or enterovirus testing. *Hosp Pediatr*. 2017;7(10):587-594.
45. Kim S, Moon HM, Lee JK, et al. Changes in trends and impact of testing for influenza in infants with fever <90 days of age. *Pediatr Int*. 2017;59(12):1240-1245. doi:10.1111/ped.13428
46. Kuppermann N, Walton EA. Immature neutrophils in the blood smears of young febrile children. *Arch Pediatr Adolesc Med*. 1999;153(3):261-266. doi:10.1001/archpedi.153.3.261
47. Roberts KB; Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. *Pediatrics*. 2011;128(3):595-610. doi:10.1542/peds.2011-1330
48. Hoberman A, Wald ER. Urinary tract infections in young febrile children. *Pediatr Infect Dis J*. 1997;16(1):11-17. doi:10.1097/O0006454-199701000-00004
49. Herreros ML, Tagarro A, García-Pose A, Sánchez A, Cañete A, Gili P. Performing a urine dipstick test with a clean-catch urine sample is an accurate screening method for urinary tract infections in young infants. *Acta Paediatr*. 2018;107(1):145-150. doi:10.1111/apa.14090
50. Tzimenatos L, Mahajan P, Dayan PS, et al; Pediatric Emergency Care Applied Research Network (PECARN). Accuracy of the urinalysis for urinary tract infections in febrile infants 60 days and younger. *Pediatrics*. 2018;141(2):e20173068. doi:10.1542/peds.2017-3068
51. Velasco R, Gómez B, Hernández-Bou S, et al. Validation of a predictive model for identifying febrile young infants with altered urinalysis at low risk of invasive bacterial infection. *Eur J Clin Microbiol Infect Dis*. 2017;36(2):281-284. doi:10.1007/s10096-016-2798-2
52. Schroeder AR, Chang PW, Shen MW, Biondi EA, Greenhow TL. Diagnostic accuracy of the urinalysis for urinary tract infection in infants <3 months of age. *Pediatrics*. 2015;135(6):965-971. doi:10.1542/peds.2015-0012
53. Brieman L, Friedman J, Olshen R, Stone C. *Classification and Regression Trees*. Washington, D.C.: Chapman & Hall; 1984.
54. Baskin MN, O'Rourke EJ, Fleisher GR. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone. *J Pediatr*. 1992;120(1):22-27. doi:10.1016/S0022-3476(05)80591-8
55. Bonsu BK, Chh M, Harper MB. Identifying febrile young infants with bacteremia: is the peripheral white blood cell count an accurate screen? *Ann Emerg Med*. 2003;42(2):216-225. doi:10.1067/mem.2003.299
56. Huppler AR, Eickhoff JC, Wald ER. Performance of low-risk criteria in the evaluation of young infants with fever: review of the literature. *Pediatrics*. 2010;125(2):228-233. doi:10.1542/peds.2009-1070
57. Scarfone R, Murray A, Gala P, Balamuth F. Lumbar puncture for all febrile infants 29-56 days old: a retrospective cohort reassessment study. *J Pediatr*. 2017;187:200-205.e1. doi:10.1016/j.jpeds.2017.04.003
58. Jain S, Cheng J, Alpern ER, et al. Management of febrile neonates in US pediatric emergency departments. *Pediatrics*. 2014;133(2):187-195. doi:10.1542/peds.2013-1820
59. Pantell RH, Newman TB, Bernzweig J, et al. Management and outcomes of care of fever in early infancy. *JAMA*. 2004;291(10):1203-1212. doi:10.1001/jama.291.10.1203
60. American Academy of Pediatrics. Project Revise. https://www.aap.org/en-us/Documents/quality_revise_recruitment.pdf. Accessed April 29, 2018.
61. Bressan S, Gomez B, Mintegi S, et al. Diagnostic performance of the lab-score in predicting severe and invasive bacterial infections in well-appearing young febrile infants. *Pediatr Infect Dis J*. 2012;31(12):1239-1244. doi:10.1097/INF.0b013e318266a9aa
62. Galetto-Lacour A, Zamora SA, Andreola B, et al. Validation of a laboratory risk index score for the identification of severe bacterial infection in children with fever without source. *Arch Dis Child*. 2010;95(12):968-973. doi:10.1136/adc.2009.176800
63. Srugo I, Klein A, Stein M, et al. Validation of a novel assay to distinguish bacterial and viral infections. *Pediatrics*. 2017;140(4):e20163453. doi:10.1542/peds.2016-3453
64. Mintegi S, Bressan S, Gomez B, et al. Accuracy of a sequential approach to identify young febrile infants at low risk for invasive bacterial infection. *Emerg Med J*. 2014;31(e1):e19-e24. doi:10.1136/emered-2013-202449
65. Singh M, Anand L. Bedside procalcitonin and acute care. *Int J Crit Illn Inj Sci*. 2014;4(3):233-237. doi:10.4103/2229-5151.141437
66. van Rossum AMC, Wulkan RW, Oudesluys-Murphy AM. Procalcitonin as an early marker of infection in neonates and children. *Lancet Infect Dis*. 2004;4(10):620-630. doi:10.1016/S1473-3099(04)01146-6
67. Wettergren B, Jodal U, Jonasson G. Epidemiology of bacteriuria during the first year of life. *Acta Paediatr Scand*. 1985;74(6):925-933. doi:10.1111/j.1651-2227.1985.tb10059.x
68. Krief WI, Levine DA, Platt SL, et al; Multicenter RSV-SBI Study Group of the Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Influenza virus infection and the risk of serious bacterial infections in young febrile infants. *Pediatrics*. 2009;124(1):30-39. doi:10.1542/peds.2008-2915
69. Levine DA, Platt SL, Dayan PS, et al; Multicenter RSV-SBI Study Group of the Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections. *Pediatrics*. 2004;113(6):1728-1734. doi:10.1542/peds.113.6.1728
70. Cruz AT, Freedman SB, Kulik DM, et al; HSV Study Group of the Pediatric Emergency Medicine Collaborative Research Committee. Herpes simplex virus infection in infants undergoing meningitis evaluation. *Pediatrics*. 2018;141(2):e20171688. doi:10.1542/peds.2017-1688